SAM
ARCT icon

Smartleaf Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Smartleaf Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30
Closed -$347 – 2732
2025
Q1 		$347 Hold
30
– – ﹤0.01% 2749
2024
Q4 		$497 Hold
30
– – ﹤0.01% 2789
2024
Q3 		$660 Hold
30
– – ﹤0.01% 2749
2024
Q2 		$733 Buy
+30
New +$910 ﹤0.01% 2481

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Smartleaf Asset Management's ARCT Position: Q2 2025 in Review

Smartleaf Asset Management sold out of Arcturus Therapeutics (ARCT) in Q2 2025, closing a stake of 30 shares — an estimated $347 sold.

Smartleaf Asset Management first reported a position in ARCT in Q2 2024 and held it in 4 quarters. The position peaked at $733 in Q2 2024. 143 funds tracked by Wall St. Rank hold ARCT as of Q2 2025.

  • Smartleaf Asset Management reported no remaining Arcturus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 30 Arcturus Therapeutics shares in Q2 2025, an estimated $347.
  • Smartleaf Asset Management first reported a position in Arcturus Therapeutics in Q2 2024 and held it in 4 quarters.
  • Smartleaf Asset Management's Arcturus Therapeutics position peaked at $733 in Q2 2024.
  • 143 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2025.

Based on Smartleaf Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.